Inhibikase Therapeutics, Inc. (IKT)

Over the past six months, Inhibikase Therapeutics, Inc. announced a proposed public offering of common stock and pre-funded warrants, followed by the pricing and closing of a $115 million public offering, contributing to a cash balance of $178.8 million at the end of 2025. The company announced its full-year 2025 financial results, highlighting the initiation of the global pivotal Phase 3 adaptive study IMPROVE-PAH for IKT-001, reporting a net loss of $48.3 million for 2025. The stock price as of March 26, 2026, was $1.63 per share, representing a decline of 31.22% over the preceding year.

No information regarding demand seasonality for Inhibikase Therapeutics, Inc.'s products and services was found in the provided search results. As a clinical-stage pharmaceutical company, its valuation is primarily driven by pipeline progress and clinical trial results rather than current revenue or seasonal product demand.

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing protein kinase inhibitor therapeutics, with a recent strategic pivot towards cardiopulmonary diseases, particularly Pulmonary Arterial Hypertension (PAH). Its current lead product candidate is IKT-001, a prodrug of imatinib mesylate, which is being advanced into a global pivotal Phase 3 study for PAH.

Inhibikase Therapeutics is headquartered in Delaware, with additional offices in Boston. The company was originally founded in 2008 and was based in Atlanta, Georgia. Inhibikase Therapeutics also engages in research and development collaborations with institutions such as Johns Hopkins University, Arizona State University, and Michigan State University.

No specific information regarding Inhibikase Therapeutics, Inc.'s brand reputation or any events that have significantly affected it in the past year was found in the provided search results.

Inhibikase Therapeutics, Inc. has significant institutional ownership, with 76 institutional owners and shareholders holding a total of 104,702,773 shares. Sands Capital Life Sciences Pulse Fund II LP is the largest single shareholder, holding approximately 14.69% of the company's outstanding shares. Individual investors possess the maximum shares in the company, holding a 39% stake, while institutional ownership is 30%. Insiders collectively own approximately $7.9 million worth of the company.